JP6250533B2 - エンドグリンポリペプチドおよびその使用 - Google Patents

エンドグリンポリペプチドおよびその使用 Download PDF

Info

Publication number
JP6250533B2
JP6250533B2 JP2014506553A JP2014506553A JP6250533B2 JP 6250533 B2 JP6250533 B2 JP 6250533B2 JP 2014506553 A JP2014506553 A JP 2014506553A JP 2014506553 A JP2014506553 A JP 2014506553A JP 6250533 B2 JP6250533 B2 JP 6250533B2
Authority
JP
Japan
Prior art keywords
eng
seq
bmp
polypeptide
endoglin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014506553A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014513951A (ja
JP2014513951A5 (cg-RX-API-DMAC7.html
Inventor
グリンベルグ，アーシャ
カストンガイ，ロザリン
ワーナー，エリック
クマール，ラビンドラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acceleron Pharma Inc
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of JP2014513951A publication Critical patent/JP2014513951A/ja
Publication of JP2014513951A5 publication Critical patent/JP2014513951A5/ja
Application granted granted Critical
Publication of JP6250533B2 publication Critical patent/JP6250533B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2014506553A 2011-04-20 2012-04-19 エンドグリンポリペプチドおよびその使用 Expired - Fee Related JP6250533B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161477585P 2011-04-20 2011-04-20
US61/477,585 2011-04-20
PCT/US2012/034295 WO2012145539A1 (en) 2011-04-20 2012-04-19 Endoglin polypeptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017224413A Division JP6803315B2 (ja) 2011-04-20 2017-11-22 エンドグリンポリペプチドおよびその使用

Publications (3)

Publication Number Publication Date
JP2014513951A JP2014513951A (ja) 2014-06-19
JP2014513951A5 JP2014513951A5 (cg-RX-API-DMAC7.html) 2015-06-18
JP6250533B2 true JP6250533B2 (ja) 2017-12-20

Family

ID=46000405

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014506553A Expired - Fee Related JP6250533B2 (ja) 2011-04-20 2012-04-19 エンドグリンポリペプチドおよびその使用
JP2017224413A Expired - Fee Related JP6803315B2 (ja) 2011-04-20 2017-11-22 エンドグリンポリペプチドおよびその使用
JP2020134862A Active JP7097930B2 (ja) 2011-04-20 2020-08-07 エンドグリンポリペプチドおよびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017224413A Expired - Fee Related JP6803315B2 (ja) 2011-04-20 2017-11-22 エンドグリンポリペプチドおよびその使用
JP2020134862A Active JP7097930B2 (ja) 2011-04-20 2020-08-07 エンドグリンポリペプチドおよびその使用

Country Status (8)

Country Link
US (3) US9932386B2 (cg-RX-API-DMAC7.html)
EP (2) EP2699590B8 (cg-RX-API-DMAC7.html)
JP (3) JP6250533B2 (cg-RX-API-DMAC7.html)
CN (3) CN108178789B (cg-RX-API-DMAC7.html)
AU (4) AU2012245439B2 (cg-RX-API-DMAC7.html)
CA (1) CA2833747C (cg-RX-API-DMAC7.html)
DK (1) DK2699590T3 (cg-RX-API-DMAC7.html)
WO (1) WO2012145539A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
AU2012245439B2 (en) 2011-04-20 2017-04-06 Acceleron Pharma, Inc. Endoglin polypeptides and uses thereof
WO2013019805A1 (en) 2011-08-01 2013-02-07 Tufts Medical Center, Inc. Treatment of heart failure and related conditions
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
HK1225742A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma, Inc. TGF-β受体II型变体及其用途
CA2962277C (en) 2013-09-20 2021-12-07 Tufts Medical Center, Inc. Methods and compositions for reducing cardiac damage and other conditions
CN105899225A (zh) * 2013-10-25 2016-08-24 阿塞勒隆制药公司 用于治疗纤维化疾病的内皮联蛋白肽
CA2931309C (en) * 2013-11-21 2022-06-21 The Brigham And Women's Hospital, Inc. Compositions and methods for treating pulmonary hypertension
JP6836400B2 (ja) 2014-03-28 2021-03-03 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション 乳がんおよび卵巣がんワクチン
GB201412290D0 (en) 2014-07-10 2014-08-27 Cambridge Entpr Ltd Novel use
EP3174550B1 (en) 2014-08-01 2020-01-29 The Brigham and Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
JP2016036322A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 血管新生因子と結合するキメラタンパク質
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
WO2016077451A1 (en) 2014-11-12 2016-05-19 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
CN108348578B (zh) 2015-08-04 2022-08-09 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
CN110498851B (zh) * 2015-11-10 2022-10-11 孙嘉琳 一种抗肿瘤蛋白内皮抑素的衍生物及应用
WO2017176938A1 (en) * 2016-04-06 2017-10-12 Acceleron Pharma, Inc. Bmprii polypeptides and uses thereof
WO2018009624A1 (en) * 2016-07-07 2018-01-11 Acceleron Pharma Inc. Tgf-beta superfamily heteromultimers and uses thereof
RS64315B1 (sr) 2017-05-04 2023-08-31 Acceleron Pharma Inc Fuzioni proteini tgf-beta receptora tipa ii i njihove upotrebe
US20210107959A1 (en) * 2018-01-03 2021-04-15 Acceleron Pharma Inc. Single-arm co-receptor fusion proteins and uses thereof
CN109402127B (zh) * 2018-09-29 2021-12-10 复旦大学附属眼耳鼻喉科医院 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用
US20220195500A1 (en) * 2019-04-26 2022-06-23 Vanderbilt University Probes for detecting rna and methods of use thereof
US20220195056A1 (en) * 2019-08-07 2022-06-23 Icahn School Of Medicine At Mount Sinai Method of treating keloids
EP4081240A4 (en) * 2019-12-03 2023-12-06 Acceleron Pharma Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF PULMONARY HYPERTENSION
WO2021167952A2 (en) * 2020-02-20 2021-08-26 The Feinstein Institutes For Medical Research Agonist antibodies against endoglin and uses thereof
KR20220021207A (ko) * 2020-08-13 2022-02-22 주식회사 나이벡 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물
US20220233714A1 (en) * 2021-01-27 2022-07-28 Vanderbilt University Nanogold-dna bioconjugates and methods of use thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8529014D0 (en) 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5462990A (en) 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1994010202A1 (en) 1992-10-28 1994-05-11 Genentech, Inc. Vascular endothelial cell growth factor antagonists
AU5541094A (en) 1992-10-30 1994-05-24 Consejo Superior De Investigaciones Cientificas Compositions and methods for modifying the regulatory activity of tgf-beta
US5830847A (en) 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US6423501B2 (en) 1996-12-13 2002-07-23 Beth Israel Deaconess Medical Center Calcium-independent negative regulation by CD81 of receptor signaling
MX9701946A (es) 1997-03-14 1998-04-30 Arturo Jimenez Bayardo Solucion oftalmica transportadora.
SI1325932T1 (cg-RX-API-DMAC7.html) 1997-04-07 2005-08-31 Genentech Inc
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
EP1695985B1 (en) 1997-04-07 2011-03-09 Genentech, Inc. Methods for forming humanised antibodies by random mutagenesis
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
AU7467898A (en) 1997-04-21 1998-11-13 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial cr signal and induce clonal anergy
EP1068241B1 (en) 1998-04-02 2007-10-10 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
KR20080068151A (ko) 2000-06-23 2008-07-22 바이엘 쉐링 파마 악티엔게젤샤프트 ＶＥＧＦ/ＶＥＧＦ 수용체 및 안지오포이에틴/Ｔｉｅ수용체의 기능을 방해하는 조합 제제 및 조성물과 이들의용도 (Ⅱ)
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
EP1638941B1 (en) 2003-05-22 2010-06-02 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US20050186208A1 (en) 2003-05-30 2005-08-25 Genentech, Inc. Treatment with anti-VEGF antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20090170767A1 (en) 2006-05-31 2009-07-02 Beth Israel Deaconess Medical Center Soluble Endoglin Compounds for the Treatment and Prevention of Cancer
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
EP3181580A1 (en) * 2006-11-02 2017-06-21 Acceleron Pharma Inc. Alk1 receptor and ligand antagonists and uses thereof
WO2008151078A1 (en) * 2007-06-01 2008-12-11 Wyeth Methods and compositions for modulating bmp-10 activity
US20100210713A1 (en) 2009-01-16 2010-08-19 The General Hospital Corporation Regeneration and survival of cardiac progenitors and cardiomyocytes with a stretch activated transcription factor
EP2209003A1 (en) 2009-01-16 2010-07-21 F. Hoffmann-Roche AG Means and methods for differentiating between fibrosis and cirrhosis
EP3384964B1 (en) * 2009-03-30 2020-03-25 Acceleron Pharma Inc. Bmp-alk3 antagonists and uses for promoting bone growth
WO2010128158A1 (en) * 2009-05-08 2010-11-11 Novartis Ag Diagnostic biomarkers for fibrotic disorders
US8795663B2 (en) * 2010-01-12 2014-08-05 Beth Israel Deaconess Medical Center, Inc. Soluble endoglin and uses thereof
AU2012245439B2 (en) 2011-04-20 2017-04-06 Acceleron Pharma, Inc. Endoglin polypeptides and uses thereof
WO2013019805A1 (en) 2011-08-01 2013-02-07 Tufts Medical Center, Inc. Treatment of heart failure and related conditions
CA2962277C (en) 2013-09-20 2021-12-07 Tufts Medical Center, Inc. Methods and compositions for reducing cardiac damage and other conditions
CN105899225A (zh) 2013-10-25 2016-08-24 阿塞勒隆制药公司 用于治疗纤维化疾病的内皮联蛋白肽
WO2016077451A1 (en) 2014-11-12 2016-05-19 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof

Also Published As

Publication number Publication date
WO2012145539A1 (en) 2012-10-26
EP2699590A1 (en) 2014-02-26
JP2014513951A (ja) 2014-06-19
CN108178789A (zh) 2018-06-19
CA2833747C (en) 2022-10-18
EP2699590B8 (en) 2019-04-17
JP2020202844A (ja) 2020-12-24
US20150307588A1 (en) 2015-10-29
JP7097930B2 (ja) 2022-07-08
US20180258156A1 (en) 2018-09-13
AU2012245439A1 (en) 2013-11-28
EP3549952A1 (en) 2019-10-09
US10981972B2 (en) 2021-04-20
EP2699590B1 (en) 2019-02-20
AU2019204979A1 (en) 2019-08-01
AU2012245439B2 (en) 2017-04-06
CN108178789B (zh) 2021-11-02
CN103781798B (zh) 2018-03-13
DK2699590T3 (en) 2019-05-06
JP2018070625A (ja) 2018-05-10
AU2019204979B2 (en) 2020-07-16
AU2020244456A1 (en) 2020-10-29
JP6803315B2 (ja) 2020-12-23
AU2017201711A1 (en) 2017-04-13
CA2833747A1 (en) 2012-10-26
CN103781798A (zh) 2014-05-07
AU2017201711B2 (en) 2019-04-18
US9932386B2 (en) 2018-04-03
US20210300991A1 (en) 2021-09-30
CN108341863A (zh) 2018-07-31

Similar Documents

Publication Publication Date Title
JP7097930B2 (ja) エンドグリンポリペプチドおよびその使用
JP6994481B2 (ja) 線維性疾患を処置するためのエンドグリンポリペプチド
JP2019210298A (ja) 血管新生および周皮細胞組成物を調節するための方法および組成物
US20210002342A1 (en) Bmprii polypeptides and uses thereof
HK40055818A (en) Endoglin peptides to treat fibrotic diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150420

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150420

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170417

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170718

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171024

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171122

R150 Certificate of patent or registration of utility model

Ref document number: 6250533

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees